Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_3
2
15%
Ph phase_1
3
23%
Ph phase_2
8
62%

Phase Distribution

3

Early Stage

8

Mid Stage

2

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
3(23.1%)
Phase 2Efficacy & side effects
8(61.5%)
Phase 3Large-scale testing
2(15.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(7)
Terminated(1)
Other(5)

Detailed Status

Completed7
unknown5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
87.5%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (23.1%)
Phase 28 (61.5%)
Phase 32 (15.4%)

Trials by Status

completed754%
unknown538%
terminated18%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_1

A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors

NCT04172506
completedphase_2

A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma

NCT04736810
completedphase_1

Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors

NCT03352531
completedphase_2

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma

NCT03866967
completedphase_2

A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)

NCT04172571
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT04172506Phase 1

A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors

Completed
NCT04736810Phase 2

A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma

Completed
NCT03352531Phase 1

Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors

Completed
NCT03866967Phase 2

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma

Completed
NCT04172571Phase 2

A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)

Completed
NCT03722147Phase 1

A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma

Completed
NCT03866993Phase 3

A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer

Completed
NCT03866980Phase 3

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

Terminated
NCT05244993Phase 2

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

Unknown
NCT05033587Phase 2

Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.

Unknown
NCT04203719Phase 2

A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer

Unknown
NCT04207463Phase 2

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Unknown
NCT04291248Phase 2

A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor

Unknown

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13